What is the current market size and future outlook for the shingrix (zostavax) market?
The shingrix (zostavax) market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to increased vaccine adoption, a rise in the need for educational campaigns, an increased focus on preventive healthcare, a rise in patient education and advocacy efforts, and a rise in insurance coverage for immunization.
The shingrix (zostavax) market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to rising geriatric population, increasing incidence of herpes zoster, rising incidence of chickenpox, increasing disease prevalence, and growing awareness about shingles and its complications. Major trends in the forecast period include innovative recombinant vaccines, advancements in vaccine development, a shift towards disease prevention over treatment, AI-powered vaccine research and development, and advanced biomarker identification for shingles susceptibility.
Get Your Free Sample of The Global Shingrix (Zostavax) Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20264&type=smp
How has the shingrix (zostavax) market evolved, and what factors have shaped its growth?
The growing adoption of vaccination is expected to propel the growth of the shingrix (zostavax) market going forward. Vaccination refers to the process of administering a vaccine to stimulate the body’s immune system to recognize and fight specific pathogens. The growing adoption of vaccination is attributed to increased awareness of its effectiveness in preventing diseases, reducing disease burden, and the development of safe and accessible vaccines. Public health campaigns, improved healthcare infrastructure, and global vaccination initiatives also contribute to its widespread acceptance. Shingrix (Zostavax) is beneficial for vaccination by providing effective protection against shingles and its complications. It is particularly beneficial for adults over 50, significantly reducing the risk of shingles recurrence and post-herpetic neuralgia. For instance, in May 2024, according to a study published by the Journal of the American Medical Association (JAMA), a US-based peer-reviewed medical journal, the shingles vaccinations covered by Medicare Part D increased by 46% in the year following the IRA policy’s implementation in January 2023. Moreover, in 2022, according to the Australian Government Department of Health and Aged Care, an Australia-based government agency, the Australian government ensured that COVID-19 vaccines were freely available to all Australians. By mid-2022, over 34 million primary vaccinations and boosters had been administered, with general practices playing a significant role in the rollout, especially in rural areas. Therefore, the growing adoption of vaccination is driving the growth of the shingrix (zostavax) market.
What are the major segments of the shingrix (zostavax) market?
The shingrix (zostavax) market covered in this report is segmented –
1) By Formulation: Recombinant Vaccine (Shingrix); Live Attenuated Vaccine (Zostavax)
2) By Indication: Shingles Prevention; Post-Herpetic Neuralgia
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/shingrix-zostavax-global-market-report
Which companies dominate the shingrix (zostavax) market?
Major companies operating in the shingrix (zostavax) market are GSK plc
How will evolving trends contribute to the growth of the shingrix (zostavax) market?
A key trend in the shingrix (zostavax) market is developing innovative products, such as non-live, recombinant subunit adjuvanted vaccines, to enhance vaccine efficacy and address age-related immune decline in vulnerable populations. A non-live, recombinant subunit adjuvanted vaccine contains specific protein components of a pathogen combined with an adjuvant to enhance the immune response. For instance, in September 2024, GSK plc, a UK-based biopharma company, launched the shingles vaccine Shingrix. Recombinant Zoster Vaccine (RZV) is a non-live vaccine offering up to 97% efficacy in preventing shingles and post-herpetic neuralgia. It is designed for adults aged 50+ and immunocompromised individuals aged 18+, administered intramuscularly in two doses. In the ZOE-50 study, RZV showed up to 97% efficacy in adults 50+ over three years, with recent data indicating over 80% efficacy lasting 6–10 years post-vaccination.
What are the key regional dynamics of the shingrix (zostavax) market, and which region leads in market share?
North America was the largest region in the shingrix (zostavax) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingrix (zostavax) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Shingrix (Zostavax) Market Report 2025 Offer?
The shingrix (zostavax) market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Shingrix (Zostavax) refers to a vaccine designed to prevent shingles (herpes zoster), a painful rash caused by the reactivation of the varicella-zoster virus. It is used for immunizing adults, particularly those aged 50 and older, to reduce the risk of developing shingles and its complications.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20264
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
